We are live on
!
Find out more
ESPR
Esperion Therapeutics
ESPR
ESPR
Delisted
ESPR was delisted on the 10th of July, 2026.
167 hedge funds and large institutions have $1.32B invested in Esperion Therapeutics in 2019 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 61 increasing their positions, 39 reducing their positions, and 25 closing their positions.
New
Increased
Maintained
Reduced
Closed
85% more call options, than puts
Call options by funds: $42.3M | Put options by funds: $22.8M
56% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 39
32% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 25
19% more capital invested
Capital invested by funds: $1.11B → $1.32B (+$216M)
2.85% more ownership
Funds ownership: 102.83% → 105.68% (+2.8%)
2% more funds holding
Funds holding: 163 → 167 (+4)
50% less funds holding in top 10
Funds holding in top 10: 6 → 3 (-3)
Holders
167
Holders Change
+4
Holders Change %
+2.45%
% of All Funds
3.63%
Holding in Top 10
3
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-50%
% of All Funds
0.07%
New
33
Increased
61
Reduced
39
Closed
25
Calls
$42.3M
Puts
$22.8M
Net Calls
+$19.4M
Net Calls Change
+$31.9M
Top Buyers
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$167M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$23M |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
+$18.1M |
| 4 |
State Street
Boston,
Massachusetts
|
+$9.62M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$9.43M |
